History
Introduction to the development history and key milestones of TheraNovis
History & Milestones
테라노비스가 핵심 바이오 기술을 바탕으로 이루어온 혁신과 검증된 가치 지표를 투명하게 공유합니다.
2025
Launch of Semi-Automated Multiplex Staining System
Secured KRW 220M in funding from a private investment fund
2024
Strategic MOU signed with AtheonBio
Strategic MOU signed with Intec Scientific
Selected for MOTIE Materials & Components Technology Development Program (KRW 10B)
Initiated establishment of Boston, USA liaison office
Secured KRW 1B in Strategic Investment (SI) from IntekPlus
Launch of Skin GeneCurator skin condition assessment service
2023
Secured KRW 300M in TIPS Investment
Secured KRW 336M in Strategic Investment (SI)
Selected for MSS Deep-Tech TIPS Program (KRW 1.5B)
Selected for Seoul-type TIPS Program (KRW 400M)
Selected for Medical Device Industry Transition Infrastructure Program
Official Launch of Phenoview (now AstraTSA)
2022
Executing the Regional Specialized Industry Development Program (MSS)
Selected for PNU Yangsan Bio Core Facility Program (KRW 600M)
Selected for the KIBO Tech-Bridge Program
Selected for the Asan Medical Center Incentive Program
2021
TheraNovis Co., Ltd. Established
MOU Signed with BioActs and Six Partner Organizations
Established Corporate R&D Centers (Hanam / Yangsan)
Continuous leap forward as a leading global diagnostic platform company